Approval came right on time for Repatha (evolocumab), Amgen Inc.'s proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, with a label that includes homozygous familial hypercholesterolemia (HoFH), "the most severely affected part of the this [FH] community, because they've inherited some sort of FH mutation from both parents," Katherine Wilemon, founder of the Familial Hypercholesterolemia (FH) Foundation, told BioWorld Today.